Needles of Hope: The Truth About Botox for Migraine

In 1992, a Beverly Hills cosmetic surgeon noticed something he couldn’t explain. Patients coming in for wrinkle treatment kept telling him the same thing: their migraines were vanishing.^[1] Dr. William Binder documented this pattern, tested it rigorously, and published his findings. But the medical community was skeptical. A wrinkle treatment for migraine? It took nearly two decades of clinical trials before the FDA approved onabotulinumtoxinA — Botox — as a preventive treatment for chronic migraine in 2010.^[2]

Since then, over one million people have received it.^[3] Yet confusion persists. Is it the same Botox that smooths foreheads? Same molecule, different mission. Does it work? For a specific group of patients — convincingly. And why would a cosmetic injection help with a neurological disease?

The answer has nothing to do with wrinkles. It has everything to do with pain.

Not Muscles. Nerves.

The first thing to understand: Botox for migraine does not work by relaxing muscles.

That was the early assumption. Migraine patients carry tension in the head and neck, so perhaps loosening those muscles was the answer. The evidence dismantled this theory quickly. Pain relief arrived before muscles relaxed.^[4] It worked in areas with no measurable change in muscle tension.^[5] And the injection map looked nothing like the cosmetic protocol.

The real mechanism is more elegant — and more surprising. OnabotulinumtoxinA enters unmyelinated C-fiber nerve endings in the trigeminal system, the brain’s primary pain highway.^[6] Once inside, it cleaves a protein called SNAP-25 — a molecular linchpin required for nerve endings to release their chemical cargo.^[7]

Picture your trigeminal nerve endings as smoke detectors. In chronic migraine, these detectors malfunction. They fire constantly, flooding the system with pain-signaling molecules: CGRP (calcitonin gene-related peptide), substance P, and glutamate.^[8] Botox doesn’t rip out the detectors. It disconnects the batteries. The alarms stop screaming.

Fewer pain signals reach the brain. Peripheral sensitization eases. And gradually, central sensitization — the process through which the brain itself becomes hypervigilant to pain — begins to unwind.^[9]

In 2004, Durham and colleagues provided the first direct evidence that Botox blocks CGRP release from trigeminal neurons.^[10] This mattered enormously, because CGRP would later emerge as the central molecule driving migraine — the very target of today’s newest migraine medications.^[11]

Two decades later, the science keeps deepening. A 2025 study by Gabriel et al. showed that in human sensory neurons, Botox doesn’t just block one protein. It downregulates an entire network of genes responsible for neurotransmitter release.^[12] The toxin doesn’t silence a single alarm. It dims the entire control panel.

The Evidence: What 1,384 Patients Taught Us

The landmark evidence comes from the PREEMPT program — two Phase III randomized controlled trials enrolling 1,384 adults with chronic migraine.^{[13, 14]}

The numbers tell a clear story. In PREEMPT 2, patients receiving Botox lost 9.0 headache days per 28-day cycle, compared with 6.7 for placebo (p < .001).^[14] Over the full 56-week program — including an open-label extension — headache frequency dropped by nearly 12 days per month from baseline.^[15]

But clinical trials are controlled gardens. Real life is wilderness. How does Botox perform in the messier, more complex world of actual patients?

The most compelling long-term data arrived in 2025. An Italian longitudinal study followed 579 patients for up to 11 years. Over 90% of long-term users achieved a 50% or greater reduction in headache days. Only 5.3% were classified as non-responders.^[18]

The pattern across trials, meta-analyses, and real-world studies is consistent: Botox works. Not for everyone. Not overnight. But for those who respond, the benefit is substantial — and it lasts.

31 Needles, 7 Muscle Groups, 10 Minutes

The treatment protocol — called the PREEMPT protocol — is precisely mapped. A trained specialist injects 155 units of onabotulinumtoxinA across 31 sites in 7 muscle groups of the head and neck:^{[19, 20]}

Frontalis (forehead) — 4 sites. Corrugator (between the eyebrows) — 2 sites. Procerus (bridge of nose) — 1 site. Temporalis (temples) — 4 sites per side. Occipitalis (back of head) — 3 sites per side. Cervical paraspinal (neck) — 2 sites per side. Trapezius (shoulders) — 3 sites per side.

Each injection delivers 5 units through a fine needle. Most patients describe it as a small pinch. The whole procedure takes 10 to 15 minutes.^[20] Doctors may add up to 40 extra units at 8 additional sites based on individual pain patterns — maximum 195 units across 39 sites.^[19]

Treatment repeats every 12 weeks. And here lies the detail that separates those who benefit from those who give up too soon: Botox for migraine is a slow build.

Most patients don’t experience the full effect until the second or third treatment cycle — six to nine months after the first injection.^[3] Benefit increases with successive cycles.^[15] The first round is the introduction. The second is the real conversation. The third is the verdict.

Who It Helps — and Who It Doesn’t

Botox is FDA-approved for one diagnosis: chronic migraine — 15 or more headache days per month, with at least 8 meeting migraine criteria, persisting for more than 3 months.^[2]

This boundary is not arbitrary. Botox has not demonstrated efficacy for episodic migraine — fewer than 15 headache days per month.^[17] The Cochrane review found no evidence to support or refute its use in that population.^[17] The PREEMPT trials enrolled only chronic migraine patients, and the results belong to them.

One encouraging finding: the PREEMPT trials included patients with medication overuse headache — the spiral of taking more and more acute medications that paradoxically worsens headache frequency — and Botox proved effective in this subgroup as well.^{[17, 21]} That matters, because medication overuse complicates virtually every other preventive approach.

One practical note: because Botox is an expensive treatment, most insurance plans — and healthcare systems worldwide — require documented failure of two or more lower-cost preventive medications (such as topiramate or beta-blockers) before approving coverage.^[3] In the U.S., Allergan offers a Botox Savings Card that can reduce out-of-pocket costs. Ask your neurologist’s office about step therapy requirements and savings programs before your first appointment.

Side Effects: The Honest Numbers

In the PREEMPT trials, side effects were generally mild. The most common compared with placebo: neck pain (9% vs. 3%), muscular weakness (4% vs. <1%), eyelid drooping (4% vs. <1%), and injection-site pain (3% vs. 2%).^[22] Fewer than 4% of patients stopped treatment due to adverse events.^[23]

Eyelid drooping — the one that worries people most — is temporary. It typically resolves within weeks and occurs when the toxin migrates near the eyelid muscles. A skilled injector following the PREEMPT protocol, placing each needle at the correct depth and distance, minimizes this risk considerably.^[20]

Another common concern — especially among men — is the “frozen face” effect familiar from cosmetic Botox. The migraine protocol distributes tiny doses (5 units per site) across 31 points, whereas cosmetic treatment concentrates 20–30 units in the forehead alone. The result: most migraine patients retain full facial expressiveness. Any subtle forehead smoothing is a side benefit, not the goal.

The safety question patients always ask: “Is it safe to put a toxin in my body?” At the migraine dose — 155 units — the amount is minute. A review of 72 cases of generalized weakness following botulinum toxin treatment found that none involved migraine patients.^[23] Systemic spread is associated with doses above 600 units — four times the migraine protocol.

Botox and CGRP Therapies: Different Tools, One Workshop

Since 2018, a new generation of migraine-specific treatments has arrived: CGRP-targeting therapies — monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and small-molecule gepants (atogepant, rimegepant). In 2024, the American Headache Society elevated CGRP therapies to first-line status for migraine prevention.^[24]

Where does that leave Botox?

Exactly where it has always been — as a foundational treatment with a different mechanism. CGRP monoclonal antibodies prevent activation of thinly myelinated Aδ-fiber nociceptors. Botox silences unmyelinated C-fiber nociceptors.^[25] They target different branches of the same pain tree.

In practice, this layered strategy is increasingly common: Botox as the base, CGRP therapy added when needed. For chronic migraine specifically, Botox remains one of only two FDA-approved preventive treatments — and the only one that requires no daily medication, no monthly self-injection, and no systemic side effects for most patients.

What 30 Years Taught Me

I’ve lived with migraine for three decades. I’ve been through the full catalogue of preventive attempts — the weight gain, the cognitive fog, the medications that felt like trading one problem for another.

When I first heard about Botox for migraine, I reacted the way most people do: the wrinkle treatment? Really?

What I didn’t understand then was that Botox for migraine was never about cosmetics. It was about an accidental discovery that led to rigorous science, which led to a treatment that silences overactive pain nerves from the outside in. The cosmetic effect was the footnote. The headline — written in the PREEMPT data, the Cochrane reviews, and the experiences of over a million patients — is about something far more important.